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Background
Th e authors have previously shown that urine neutrophil 
gelatinase-associated lipocalin (NGAL), measured by a 
research ELISA, is an early predictive biomarker of acute 
kidney injury (AKI) after cardiopulmonary bypass (CPB). 
Th e availability of a standardized clinical platform for 
NGAL measurements could revolutionize renal diag-
nostics, especially in intensive care situations.
Methods
Objective: Th e ﬁ rst objective of the present study was to 
determine whether an NGAL immunoassay developed 
for a standardized clinical platform (ARCHITECT® ana-
ly zer, Abbott Diagnostics) correlates with the research-
based assay. Th e second objective was to determine the 
utility of the standardized NGAL immunoassay as a 
predictive biomarker of AKI after CPB in a large 
prospective cohort.
Design: Prospective cohort study
Setting: Children’s hospital at a large US academic 
medical center.
Subjects: 196 children undergoing elective CPB for 
surgical correction or palliation of congenital heart 
lesions between January 2004 and June 2006.
Intervention: None.
Outcomes: Th e primary outcome variable was the 
development of AKI, deﬁ ned as a 50% or greater increase 
in serum creatinine from baseline. Other outcomes 
included percent change in serum creatinine, days in 
AKI, dialysis requirement, length of hospital stay, and 
mortality.
Results
In a pilot study with 136 urine samples (NGAL range, 0.3 
to 815 ng/ml) and 6 calibration standards (NGAL range, 
0 to 1000 ng/ml), NGAL measurements by research 
ELISA and by the ARCHITECT assay were highly corre-
lated (r = 0.99). In a subsequent study, serial urine NGAL 
measurements were obtained by ARCHITECT assay. Of 
the 196 children undergoing CPB, AKI developed in 99 
patients (51%), but the diagnosis using serum creatinine 
was delayed by 2 to 3 d after CPB. In contrast, mean 
urine NGAL levels increased 15-fold within 2 h and by 
25-fold at 4 and 6 h after CPB. For the 2-h urine NGAL 
measurement, the area under the curve was 0.95, 
sensitivity was 0.82, and the speciﬁ city was 0.90 for 
prediction of AKI using a cutoﬀ  value of 100 ng/ml. Th e 
2-h urine NGAL levels correlated with severity and 
duration of AKI, length of stay, dialysis requirement, and 
death.
Conclusions
Accurate measurements of urine NGAL are obtained 
using the ARCHITECT® platform. Urine NGAL is an 
early predictive biomarker of AKI severity after CPB.
Commentary
Acute kidney injury (AKI) is estimated to occur in 5% of 
hospitalized patients and as many as two thirds of 
intensive care unit patients [2]. Early detection of acute 
kidney injury could facilitate timely intervention before 
irreversible injury has occurred, with the goal of limiting 
morbidity and mortality. Unfortunately, the current 
diagnosis of AKI is based predominantly on changes in 
serum creatinine, which may not manifest for several 
hours after the initial insult. Th ere is an ongoing search 
to identify early biomarkers of AKI that would play a role 
similar to that of troponin in acute myocardial infarction. 
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rapidly released by renal tubules in response to injury. 
Urinary NGAL is an early predictor of AKI in a variety of 
acute clinical settings [3]. Most of the studies evaluating 
NGAL as a predictor of AKI used a research-based 
ELISA assay. Th e availability of a standardized clinical 
platform for NGAL measurement would make this 
promising new biomarker more widely available.
Th e current study by Bennett and colleagues was 
conducted to accomplish two goals [1]: Th e ﬁ rst was to 
determine whether a new standardized clinical assay for 
urinary NGAL correlated closely with the research assay. 
Th e second was to determine whether urinary NGAL 
levels obtained using the new clinical assay could accu-
rately predict AKI after cardiopulmonary bypass (CBP) 
in children. Th e authors successfully accomplished both 
goals. Th e new clinical assay was highly correlated with 
the research assay (r=0.99) and highly predictive of post-
CPB AKI. A urinary NGAL threshold of 100 ng/ml at just 
two hours post-CPB predicted the subsequent develop-
ment of AKI with an area under the receiver operating 
characteristic (ROC) curve of 0.95 and a corres ponding 
sensitivity and speciﬁ city of 0.82 and 0.90. Furthermore, 
this same 2-hour NGAL level correlated with severity 
and duration of AKI, length of stay, dialysis requirement, 
and death.
Th is was a well-done study showing the promise of a 
new clinical assay and aﬃ  rming the signiﬁ cant delay in 
diagnosing AKI via changes in serum creatinine, which 
did not show statistical diﬀ erences until 48 hours after 
CPB. Th ough this study was limited to children under-
going CPB, subsequent studies and a meta-analysis have 
conﬁ rmed the utility of both urinary and plasma/serum 
NGAL for the early detection of AKI in other patient 
populations, including adults [4] and in mixed medical-
surgical intensive care unit patients [5]. Importantly, the 
relationship between urinary NGAL and AKI after CBP 
in adults varies with baseline renal function [6]. 
Postoperative NGAL best indentiﬁ ed AKI in patients 
with baseline glomerular ﬁ ltration rates (GFR) of 90 to 
120 ml/min. In patients with baseline GFR <60 ml/min, 
urinary NGAL did not diﬀ er at any time between those 
who did and did not develop AKI.
Recommendation
NGAL and other novel biomarkers such as cystatin C [7] 
can lead to rapid detection of AKI. A strategy of early 
biomarker-driven detection and subsequent intervention 
may lead to improved outcomes and warrants further 
study.
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